Table 1.
Baseline characteristics of included studies.
| Country | First author | Year | Registration number | Study design | Phase | Research scale | Pembro(N) | Control(N) | Pembrolizumab therapy | Pembro dose and schedule | Control therapy | Molecular subtype | Median age of Pembro group (years) | Median age of control group (years) | Median follow-up time (months) | Outcomes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Korea | Sun Young Rha (32) | 2023 | KEYNOTE-859 | RCT | III | Multicenter | 790 | 789 | pembrolizumab plus chemotherapy | Pembro (200mg IV 21-day cycle) | placebo plus chemotherapy | HER2 - | 61(52-67) | 62(52-69) | 31 | ORR, DoR, OS, PFS, AEs, irAEs, OS-12, OS-24, PFS-12, PFS-24 |
| Japan | Kohei Shitara (33) | 2020 | KEYNOTE-062 | RCT | III | Multicenter | 256 | 250 | single-agent pembrolizumab | Pembro (200mg IV 21-day cycle) | placebo plus chemotherapy | HER2 - | 61(20-83) | 62.5(23-87) | 29.4 | ORR, DoR, OS, PFS, AEs, irAEs, OS-12, OS-24 |
| Japan | Kohei Shitara (33) | 2020 | KEYNOTE-062 | RCT | III | Multicenter | 257 | 250 | pembrolizumab plus chemotherapy | Pembro (200mg IV 21-day cycle) | placebo plus chemotherapy | HER2 - | 62(22-83) | 62.5(23-87) | 29.4 | ORR, DoR, OS, PFS, AEs, irAEs, OS-12, OS-24 |
| Japan | Kohei Shitara (34) | 2025 | LEAP-015 | RCT | III | Multicenter | 443 | 437 | pembrolizumab plus lenvatinib plus chemotherapy | Pembro (400 mg IV, 42-day cycle) | single-agent chemotherapy | HER2 - | 62(21-84) | 61(24-84) | 32.2 | ORR, DoR, OS, PFS, AEs, irAEs, OS-12, OS-24, PFS-12, PFS-24 |
| Korea | Yung‐Jue Bang (35) | 2019 | KEYNOTE-059 | Single-arm | II | Multicenter | 25 | NA | single-agent pembrolizumab | Pembro (200mg IV 21-day cycle) | NA | HER2 - | 64(21-82) | NA | 13.8 | ORR, DoR, OS, PFS, AEs, irAEs, OS-12, OS-24, PFS-12 |
| Korea | Yung‐Jue Bang (35) | 2019 | KEYNOTE-059 | Single-arm | II | Multicenter | 31 | NA | single-agent pembrolizumab | Pembro (200mg IV 21-day cycle) | NA | HER2 - | 62(32-75) | NA | 17.5 | ORR, DoR, OS, PFS, AEs, irAEs, OS-12, PFS-12 |
| Japan | Akihito Kawazoe (36) | 2020 | KEYNOTE-659 | Single-arm | II | Multicenter | 54 | NA | single-agent pembrolizumab | Pembro (200mg IV 21-day cycle) | NA | HER2 - | 66(32-75) | NA | 16.9 | ORR, DoR, OS, PFS, AEs, OS-12, OS-24, PFS-12, PFS-24 |
| Japan | Kensei Yamaguchi (37) | 2022 | KEYNOTE-659 | Single-arm | II | Multicenter | 46 | NA | single-agent pembrolizumab | Pembro (200mg IV 21-day cycle) | NA | HER2 - | 65(30-75) | NA | 17.1 | ORR, DoR, OS, PFS, AEs, OS-12, OS-24, PFS-12, PFS-24 |
| London | Ian Chau (38) | 2020 | NCT02443324 | Single-arm | I a/b | Multicenter | 28 | NA | pembrolizumab plus ramucirumab | Pembro (200mg IV 21-day cycle) | NA | HER2 - | 63(31-83) | NA | 26.4 | ORR, DoR, OS, PFS, AEs, irAEs, OS-12, PFS-12 |